Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

The effects of sorafenib treatment on the CD4+T cell population

ABSTRACT: The effects of sorafenib treatment on the CD4+T cell population

PROVIDER: PRJNA1181542 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR31208700_1.fastq.gz	Fastqsanger.gz
	SRR31208700_2.fastq.gz	Fastqsanger.gz
	SRR31208701_1.fastq.gz	Fastqsanger.gz
	SRR31208701_2.fastq.gz	Fastqsanger.gz
	SRR31208702_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 12

Similar Datasets

The effects of sorafenib treatment on the CD4+T cell population

Project description:To investigate the impact of sorafenib treatment on gene expression in CD4+T cells, we performed RNA sequencing on CD4+T cells treated with sorafenib and on control CD4+T cells that were not treated with sorafenib. Specifically, our study focused on the expression of immune related genes, and we observed an downregulation in the expression of TCR genes.

2025-05-14 | GSE280959 | GEO

The effects of sorafenib treatment on the T helper cell (Th9) population

Project description:The effects of sorafenib treatment on the T helper cell (Th9) population

| PRJNA1181543 | ENA

The effects of sorafenib treatment on the regulatory T cell (Treg) population

Project description:The effects of sorafenib treatment on the regulatory T cell (Treg) population

| PRJNA1176509 | ENA

The effects of sorafenib treatment on the T helper cell (Th9) population

Project description:To investigate the impact of sorafenib treatment on gene expression in Th9 cells, we performed RNA sequencing on Th9 cells treated with sorafenib and on control Th9 cells that were not treated with sorafenib. Here, we found that the up regulation of genes about Il-9.

2025-05-14 | GSE280958 | GEO

The effects of sorafenib treatment on the regulatory T cell (Treg) population

Project description:To investigate the impact of sorafenib treatment on gene expression in Treg cells, we performed RNA sequencing on Treg cells treated with sorafenib and on control Treg cells that were not treated with sorafenib. Specifically, our study focused on the expression of immune-suppressive related genes, and we observed an upregulation in the expression of Tgf-β1 (Transforming Growth Factor-β1), Prf1 (Perforin 1), Gzma (Granzyme A), and Il10 (Interleukin 10).

2025-01-05 | GSE280126 | GEO

Comparison of gene expression between Hep3B tumors treated with sorafenib plus mouse-IFN treatment and those treated with sorafenib alone

Project description:In our experiments with a xenograft model, mouse-IFN (mIFN) treatment was suggested to exaggerate the antitumor effects of sorafenib on hepatocellular carcinoma in vivo. We explored how mIFN enhances the in vivo antitumor effects of sorafenib.

2017-11-01 | GSE102863 | GEO

The effects of sorafenib treatment on the Hep1-6 tumor tissue

Project description:This study aimed to investigate the transcriptomic changes in subcutaneous Hepa1-6 tumor tissues of mice following intraperitoneal administration of sorafenib, a tyrosine kinase inhibitor, versus a control solvent. Mice were injected with either sorafenib or the control solvent four times, according to the experimental design. After the treatment period, tumor samples were collected and subjected to RNA sequencing (RNA-seq) to analyze the gene expression profiles. The results from this RNA-seq analysis provide insights into the molecular mechanisms underlying the response of Hepa1-6 tumors to sorafenib treatment, potentially identifying novel therapeutic targets and biomarkers for hepatocellular carcinoma.

2025-01-05 | GSE283371 | GEO

The effects of sorafenib treatment on the Hep1-6 tumor tissue

Project description:The effects of sorafenib treatment on the Hep1-6 tumor tissue

| PRJNA1193538 | ENA

Epigenetic regulation of the DNMT1/MT1G/KLF4/CA9 axis synergizes the anticancer effects of sorafenib in hepatocellular carcinoma

Project description:Sorafenib, a multiple-kinase inhibitor, has been widely used as a first-line anticancer drug for advanced hepatocellular carcinoma (HCC). However, the development of drug resistance to sorafenib is frequently observed in clinical applications. Potential non-kinase targets of sorafenib have not been well documented and may provide insights into reversing drug resistance. Herein, we report that sorafenib exerted its anticancer effects by activating metallothionein 1G (MT1G) expression. MT1G served as a novel marker in HCC and correlated well with patient survival. MT1G overexpression suppressed the cellular proliferation, migration, invasion, and tumor formation of HCC, and sensitized cells to sorafenib treatment. However, the disruption of MT1G attenuated sorafenib’s anticancer effects. Mechanistically, sorafenib upregulated MT1G expression via hypomethylation of its promoter region by binding and inhibiting DNA methyltransferase 1 (DNMT1) and increasing its promoter accessibility in HCC cells. The activation of MT1G also inhibited CA9 transcription through the degradation of HIF1a as mediated by KLF4. Our collective data revealed that sorafenib exerted its anticancer effects through epigenetic regulation of the DNMT1/MT1G/KLF4/CA9 axis in HCC, and that the activation of MT1G might constitute a strategy for reversing sorafenib resistance.

2022-04-30 | GSE192771 | GEO

RNA-sequencing of HCC patients undergoing sorafenib treatment

Project description:RNA-sequencing of hepatocellular carcinomas at various stages of sorafenib treatment

| EGAS00001005662 | EGA